of pipeline six Thank in We're medicines different you, Stéphane. advancing our modalities.
the both viral cells the own of of antigen peptide had of our volunteers we've using the on the profile across we and tolerability expressing pleased clinic. consistent in vaccines start with over expected course where demonstration preclinical body's programs emerging data X,XXX to fundamentals with continued that the repeated based wealth the seven and safety to-date. well We're a and So immunogenicity, which me healthy of let treated prophylactic with translate
addition the in studies. the first expectations. But me latest to exceeded other I The continued them, review X progress. let is These our Phase before success update on here. RSV respective data programs CMV you dose Zika their Phase briefly patients X and have Both
mRNA-XXXX dose vaccination shown be For we at lowest where Society the International fully preclinical presented to late with Zika, was also in conference tested. protective Vaccines October, at data for the
the I'm program, that dosed. subject as report hMPV/PIVX age with noted first the Stéphane de-escalation study to pleased started has the On
with We durability subjects also XX Disease at continued virus to presented chikungunya data with post And program, seropositive October. chikungunya the good our finally, vaccine at vaccination. in of we XX.X% months see X-month immunogenicity Infectious to Week
So that of viruses, common lengthened babies a are is for The we're is a disease let's back mothers of a born CMV it's herpes pregnancy. largest birth infected and get defects herpes to which pathogen once And means member life. CMV other during in associated to who family is the infected it's CMV. viruses. like with virus,
U.S. year is the the newborns against XX,XXX significant there approximately years. burden each is in year any vaccines on Currently despite aren't repeated XX last disease the The attempts infected and market CMV with infected of each over
inadequate Now surfaces are prior uses first immunization the we port which line and believe the the has virus of the been the against virus. failures for infect that the pentameric complex entry so that epithelial for body cells, to a reason cells either
the This the they pentamer transported of five membrane. is to assemble distinct made cell proteins before to have are inside that
to make is time, obviously traditional a this trying at one protein structure challenging. So using recombinant technologies
be a of technology However, overcome enables our components. our vaccine, mRNA-based because with simultaneous five translation this challenge can
encode bottom the for six gB. contains this half on which sequences, shown actually of for five mRNA As encodes one slide, that this mRNA-XXXX pentamer and of
of vaccine simple of which important the already demonstrating with receptor. is that showed starting that included infection, prevention the good And a a provides CMV gB half efficacy. studies single-protein Now, relatively only is very the point thing gB cases recombinant for us prior with
constantly if not. next So let And this in fighting with infected frame one past our Every or is has the me the slides. infection. us lifelong of and we're two we CMV data carriers been system chronic either immune have
we If antibodies never our blood So serum called been is in we've we're that infected have seronegative. of the and seropositive.
I subjects seropositive our in Phase both Now study. enrolled seronegative and were
mediate looking virus levels mRNA-XXXX of two cell infect the pentamer gB the for titers that the at fibroblast. the cells two be in we'll antigen, the ability So the of epithelial different and antibody and neutralizing to for types, the encodes each. general
of a will of functional either ability we important, virus' at to the readout. is because That titers we're the neutralize that So can blood subject about talking infect look type cell. in
at are trial. sets we from data all-in-all, So four looking this
table placebo GMT labeled post where each dose to for X,XXX, down fourth for infection. start XX,XXX seronegative which on the the second in in vaccination, levels. tested, the the The to were rows two of of see against basically slide zero Let's neutralizing levels epithelial with and for going the XXX-microgram attention half XX- you row the and shows half The dose titer will roughly table. XX- and XX,XXX your group placebo top titers top cell I'm draw the subjects XX. antibody
infected previously titer the CMV titers the focus second sixth The the level people, of that CMV row the neutralizing level is seropositive shows in row seropositives. the seen have XXXX. This who been is to of on by
with subjects the trial. neutralizing The cell achieved is the to fold the what in vaccine higher our natural ratio in immune elicited relative seen epithelial infection response row level antibody between with than right and that shows an subjects is microgram above that from XXX against X.X the seropositive levels X.X doses and mRNA-XXXX XX At infection. seen seropositive
have is why to lower an because pregnant unborn their reason been The of rate CMV point a this have observed children. of important to is transmission CMV seropositive the women that
mRNA previous results that the these vaccine demonstrates not it our strong vaccines exceeded immunological of and and So levels, are have seropositive striking potency platform.
similar the for comparison antibody of against a The bottom half neutralizing table fibroblast. shows titers
vaccine-induced our subjects. titer antibody to neutralizing seropositive levels see similar in Here, we levels
achieved So goal we've here the well. as
Taken seronegative effectively to individuals. well subjects level that together, at/or immunizes data interim these seropositive mRNA-XXXX shows above
of the this XX representation shows the in subjects Slide for time the trial. the only same data seropositive
titers. second started increases antibody both antibody neutralizing subjects with we The was in marked see the off as placebo Here, XXXX. and first average with described neutralizing After titers. level vaccination, I
well With individuals And we It's noting to above fold boost benchmark. boosting this a vaccinations cells has for X fold XX the prior to vaccines. cells, above X neutralizing as as levels, with CMV-seropositive increase epithelial with And XX baseline. worth seropositive true see been both increase. well epithelial fibroblast. So, is the that the of observed a we antibody this see not fibroblast
safe terms And than injection adverse events tolerated seem one vaccine systemic be in to pain, common after included Local more with redness to In of myalgia. events. adverse serious was events at fatigue no fever subjects The and the flu-like seropositive more site. safety were in most the and generally and common well and be tolerability, severe adverse vaccination. swelling more and adverse of events chills the tend symptoms
with elicit tend see in are a our That specific trial response. In to the other other to this are that potency words, events a the and expects vaccine tolerability a adverse profile in immune type vaccine healthy volunteer seen said, the trials. of we've consistent with and one safety vaccine they to correlate that of
dose. second As a reminder, data interim far the data I've analyzed thus the the month described one as after
a six at out and seropositive-neutralizing is small this year The slide preliminary have seronegative see you solid following regimen regimen zero, from three-dose And Our can which a line of subjects the X-dose epithelial the level gray is two for of infection. results data on a against cell regimen. months. titers cohort to we
relatively is mRNA out a we I gets seropositive at least of remain And zero an at a help, with is see month our of know by eliciting My a that, further shallow decline to that at are expectation to so is starts at/or durability the above three platform. you the feature boosted can they over strong that, and time. T-cell everyone level, function described of this month inherent six, previously level vaccine year, which
was data. out we're and boosted community vaccine We've seropositive of who well titers, summary, CMV their seronegative very while to don't have these we baseline believe a were successfully in early the above were subjects generate generally something level seen I pleased has that So neutralizing year. shown to with mRNA-XXXX durability safe immunized and tolerated, before. to subjects, evidence
newborns. dose prevention are X these a suggests importantly, moving prevention Phase preparations trial the and in endpoint for basis X,XXX underway, a path X to that include with approval opposed to childbearing population a are infection of using that a X a in believe We're excited licensure based this licensure start well would of by quickly primary to achievable regulatory results a FDA study. phase subjects. We be with only on feedback age would of as Phase is demonstrating and confirmation less women than infection as
to innovative a CMV. clear unmet age we the opportunities vaccines pricing a pediatricians, can very down commercial get one need, be effort large Prevention women targeting a significant potential. population a for any other childbearing expansion. And focused of which for motivated there of the quickly aren't vaccines Currently, translate multi-billion opportunity. will The CMV road with on calling in into we're OB/GYNs should expect label to and sales similar market on is sales highly dollar assuming and annual
that vaccine the T-cells trial. encode. both Moving enrollment modality. Recall ASCO NCI and a had pretreated five new They our in of to NCI completed heavily ability any cancer demonstrated given as vaccines personalized boost the a vaccine to as their vaccine that cancer our we agent to they the induce attempt single has the the They now we antigens personalized subjects an seen of agent population. in used The cancer expansion of to that patient responses at tumor-infiltrating have five lymphocytes a further not to these in patients. single against
and randomized that personalized of actively combination program versus the in to PCV vaccine with vaccine trial the In of where contrast, in towards end, And with Phase enrolling inhibitor ability stages melanoma we're earlier patients the a synergy for a to compare the cancer PD-X personalized primarily in work our in disease. is KEYTRUDA X KEYTRUDA designed treatment in we adjuvant patients will setting. cancer with of alone our testing
a X cancer KRAS lung is And getting And to these for in approach lot is prevalent target Phase use combination by being vaccine partner a KRAS four attention KEYTRUDA PCV run for and targeting our the as our mutations to pancreatic is as cancer most also vaccine. trial enroll. X the – colorectal Merck. cancer Phase is with trial continues The ongoing. KRAS our And our a The finally, days. of
modality. intratumoral the Moving to
this we encodes and focus longer patients the We durvalumab. advanced to in which a arm OXXX The we'll with a have escalation once of is with move of moving and dose our intend sphere forward co-stimulator Phase is of cohort combination ligand, programs patients Starting ligand combination completing immune currently monotherapy and XX. with efforts OXXX with interleukin with Phase just ligand with the X a ovarian mRNA-XXXX, on confirmation potent and the dosing OXXX Triplet but X cancer, We're monotherapy which no in three ligand complete. into OXXX durvalumab, the activation. cohort
which ongoing. trial combination cytokines in is We tumor-specific two the this cohorts. X Phase IL-XX for triplet to and and with for ligand encodes pro-inflammatory several of The mRNA-XXXX intend durvalumab IL-XX OXXX test
is IL-XX our with partnered ongoing. Finally, a rationale program also AstraZeneca on based similar
additional Phase the AstraZeneca increasing partner our Recall of trial with here. localized In sites the VEGF our Europe in is modality enrollment goal ongoing. regenerative X that, has opened
So starting shared let systemic the minutes spend last few R&D me our the on at therapeutics we with recent Day. data
for Antibodies both an that As a and chain light encodes reminder, complex together. consisting virus. a antibody against proteins heavy are come a mRNA-XXXX chikungunya of
and to it. chain. two light where So Once expect mRNAs, that we the heavy formed, the encodes one in encodes secreted mRNA-XXXX that antibody chain the for for the be one measure can would includes we bloodstream,
CHKV-XX CHKV-XX mRNA-XXXX the the was more antibody So, here the are gave a We meaning a dose-dependent manner the more translation Phase of saw antibody you X data. in made.
and one doses level be per of well kg exactly months the we the the had predicted, per the microgram at show that is X.X stay protein the the as chikungunya half-life at one of is microgram such to the behavior antibody the dose. predicted Administering level And middle against pre-specified four mg amount ml level in to above expected least excess mRNA-XXXX the production of protective for as protein at that virus. high
liver in the disease using enzymes inset, children born methylmalonic production we is the cells acidemia. delivery protein relevant with intracellular direct to This rare As as synthesis you propionic genetic of can technology as case and in see acidemia the of hours. think within this starts is of in
the in this subject the slide of inter measured proteins. to as recombinant to delivery direct by whole. words, is within on which to apparent define subject, low remarkably technology range seen within our it given in expression but final to important increase variance a response variability subjects, a what of population protein The the relates XX% In to can the relationship without is the our similar not as variability point dose other XX%. a coefficient between is with make ability just as is This
active made also mRNA-XXXX that is show the expected. as We antibody using
the tested against proportion least at here antibody And a of Here from neutralize an blood the assay. serum the in be virus. the whom in as the it collected is shown subjects dilute virus and is still you of hundredfold and patients to able can
test the though me had premedications the the of able mRNA-XXXX were on without to steroids review we if toxicology, needed. Let safety course information. option investigator the of using steroid Based preclinical
placebo that a to dose, and middle distinguish For relates reached recall of doses, it levels arm not could drug the we and the safety. between as protein. low middle therapeutic the potentially difference we at And
resolved And to infusion-related fact hours nanoparticles large. typically were anticipated the started within we protocol. were at lipid clinically proteins reactions time These with the in occurred that subject by changes not high the in did adverse with of see or dose and and liver associated at see or we recombinant infusion up serious are intervention. in They function We require the medical did the to got morning sleep in and went did kidney see any not not events tests. the
To would model humans pharmacology technology, expect performance the based the understand preclinical our on that our we in clinical team to of ask I'd exposure experience. the model animal
are can exactly So at protein human confidence see the for where the the levels clinical individual expected. landing where here And would in dose level. the dots you fall shaded to areas each data XX% we expect intervals solid
lipid mg because for delivery it rare X.X And first of our no other disease of it confidence to activity the in using nanoparticle. per kg level program same with in our is increases potency. the is because deliberate species Our MMA words loss important technology preclinical predicted the human dose translates this from
in steroid explicitly infusion-related part further the steroids the X.X of first we the not and completely premedication the mg that question include we that eliminate did can add reactions kg is reduce or whether per seen. the dose study we've to Given
explore per of splitting doses we're intend week apart to dose pharmacology So both and as X.X per two mg with as the do inclusion kg dose X.X of mg without of giving to the steroids. steroid mRNA-XXXX kg level continuing the and well by the at so premedication one
show trial. I look to from data continuing to forward emerges this as it So the
levels were saw a species potency in translation mRNA-XXXX. In it summary, Chikungunya chikungunya the no species predicted our with a bring functional virus. antibody we're antibodies the profile really with from of The into of happy increase antibodies results dose-dependent against We program loss and of humans. when to we
was being well-tolerated MMA antibodies as we in well like also for therapeutic results same at the mRNA-XXXX LNP volunteer a that where produced. these delivery technology a mRNA-XXXX. rare saw healthy population And disease importantly, use of programs levels dose bode our
on So similar MMA to brings intracellularly. in quick deficiency a inborn provide this of PA. the both caused PCC let intracellular of protein error caused These and me me modality by or which by deficiency update enzyme And and metabolism MUT therapeutics. this act you are diseases are
its currently there Phase rare rare patients vouchers. preparing Phase and is IND and and proteins approval And I designation, status standpoint, orphan MMA and to replace we're designations. similar FDA pediatric start status, pediatric FDA disease for which had bring PA will and the mRNA-XXXX two program Both mRNA-XXXX orphan these fast-track FDA associated designation active and disease trial have the closer protein recently compounds recruiting The metabolism From open. the disease Our PA to normal. MMA the programs regulatory aim shortly. to programs levels qualify drug X/X a a acidemia upon have study for EMA
gone to the older summer they regarding FDA than XX. bracket for the between the cohort age include had of Now adolescents during and allowed to the and of initial limited back by this we expansion agency ages MMA And the to X. XX was patients
been we're by enrollment protocol weeks continuing to the with past of approved FDA the few IRBs first amended the While the further the dialogue this regarding few institutions. in has modification criteria
progress on I our updating you look So to forward soon.
and activities has subsequent the a at age restrictions. we similar the And leading initial have of centers. fast PA the track design begun designations, academic start-up IND and opening similar following
close and on next well start lists catalysts. CMV on And as Phase as the slide Phase eventual me the PA with readout clinical Let anticipated the the and XX focus X X/X MMA which steps upcoming and trials. I'll you
the With turn that over me let call Lorence. to
